SKE's 2023FY: 140 Million USD Net Profit, Staggering 1043.51% YoY Increase

Business by 2FIRSTS
Mar.27.2024
SKE's 2023FY: 140 Million USD Net Profit, Staggering 1043.51% YoY Increase
Yinghe Technology's subsidiary SKE reported a staggering 1043.51% increase in net profit in their 2023 annual report.

On the evening of March 26th, Yinghe Technology (300457) released its annual report for 2023. The report revealed that its subsidiary, SKE, achieved a total operating income of 3.34 billion yuan, with an operating profit of 1.17 billion yuan. The net profit was approximately 1 billion yuan (140 million USD), representing a year-on-year growth of 1043.51%.

SKE's 2023FY: 140 Million USD Net Profit, Staggering 1043.51% YoY Increase
Sikary Performance Chart | Image source: Yinghe Technology

 

A report has stated that Sikary has achieved good development in countries such as the UK, Germany, Poland, the Netherlands, and Malaysia.

 

In 2023, the headquarters of Yinghe Technology achieved operating income of 9.75 billion yuan, an 8.09% year-on-year increase. It also achieved a net profit of 554 million yuan, a 13.62% year-on-year increase.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Russia’s Rostov Region Eyes Full Vape Sales Ban, Signals Tighter Tobacco Retail Rules
Russia’s Rostov Region Eyes Full Vape Sales Ban, Signals Tighter Tobacco Retail Rules
Russia’s Rostov region is preparing to pursue a region-wide ban on vape sales and is also signaling support for broader regional powers to tighten tobacco retail rules. A regional lawmaker said the initiative aligns with a State Duma bill that would allow regions to impose vape sales bans—an initiative he said has presidential backing.
Jan.28 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
A new lawsuit in California state court accuses Stiiizy Inc. of steering high-THC vape products toward teens through youth-appealing branding and weak age verification, alleging the plaintiff’s underage use was followed by cannabis-induced psychosis-related symptoms and significant personal harm.
Feb.06 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24